Pfizer, Medtronic, Hinge Health emerge as AI healthcare leaders

The three stocks emerge from a broader Transformative AI Healthcare screener that identified 43 companies total, but these three exemplify distinct pathways for AI to reshape healthcare economics. Pfizer, as a US$62.3b Global Biopharmaceuticals Business with a smaller US$1.4b segment adjustment, operates at the intersection of large-scale pharma and AI-powered drug development; its late-stage pipeline in oncology, rare disease, and obesity positions it to reshape earnings mix over time, though recent margins have come under pressure and revenue is expected to decline for a few years even as earnings are forecast to grow. Medtronic, generating roughly US$36.4b in annual revenue across Cardiovascular (US$14.0b), Neuroscience (US$10.3b), and Medical Surgical (US$8.8b), brings AI directly into clinical workflows through surgical automation, but must contend with execution risk from product recalls and the complexity of a Diabetes spin-off. Hinge Health, smaller at US$7.2b market value with tightly-focused healthcare software revenue of US$720.1 million, represents a pure-play digital care model pairing AI motion tracking and wearables with expanding gastrointestinal care (via the Cylinder Health deal) and margin expansion targets. Across all three, the tension is consistent: transformative AI potential clashing with near-term financial headwinds and execution challenges.